What did @lizdamyl actually say?
Honestly? Almost nothing, verbally. The transcript is just "Carry on. Carry on. Carry on. Carry on. I'm getting so excited." That's it. The real message lives in the visual before-and-after framing, the PCOS awareness hashtag, and the tag to a GLP-1 telehealth platform called JoinFridays. The implied claim is that GLP-1 medication helped a person with PCOS achieve a visible body transformation. There are no spoken medical assertions to fact-check in isolation, which makes the video's influence almost entirely dependent on what viewers project onto it.
This format is increasingly common in GLP-1 content, and it's worth being direct: a wordless transformation video with a disease hashtag carries implicit medical messaging whether the creator intended that or not. The 119,900 views suggest a lot of people with PCOS are watching and drawing their own conclusions.
Does the science back up the implied claim?
The implied claim, that GLP-1 medications can support meaningful weight loss in people with PCOS, is actually reasonably well-supported. But the nuance matters a lot, and a silent TikTok video can't deliver nuance.
A 2022 randomized controlled trial by Jensterle et al. published in Reproductive Biology and Endocrinology found that semaglutide produced significantly greater weight loss than metformin in women with PCOS and obesity over 24 weeks. A 2023 review by Cena et al. in Journal of Clinical Medicine noted that GLP-1 receptor agonists appear to address several PCOS-related metabolic issues including insulin resistance and androgen excess, not just weight. That's clinically meaningful context.
However, PCOS is a heterogeneous condition. Not everyone with PCOS has the same hormonal profile, the same insulin sensitivity, or the same response to GLP-1 therapy. Before-and-after videos flatten all of that into one story.
What did they get wrong, or right?
Credit where it's due: tagging a regulated telehealth platform rather than a random supplement seller is a better look than most GLP-1 content on TikTok. Using the PCOS awareness hashtag without making wild claims about curing hormonal disorders is also, relatively speaking, responsible.
What's missing is the harder conversation. GLP-1 medications for PCOS are still largely off-label use. The FDA has approved semaglutide for chronic weight management and type 2 diabetes, not PCOS specifically. That distinction matters for patients trying to get insurance coverage or understand their options. A transformation video tells you someone lost weight. It doesn't tell you about the side effects they managed, the dietary changes they made, whether they're on brand-name or compounded semaglutide, or what their labs look like now. Those omissions aren't lies, but they shape a misleading picture of effortless success.
What should you actually know?
If you have PCOS and you're considering GLP-1 therapy, here's the grounded version of what this video implies.
- GLP-1 receptor agonists have shown real promise for metabolic symptoms of PCOS, including weight, insulin resistance, and in some studies, androgen levels. The evidence base is growing but still limited compared to type 2 diabetes research.
- Compounded semaglutide and brand-name Wegovy or Ozempic are not the same product. FDA has flagged this repeatedly. The formulation, inactive ingredients, and quality controls differ. Do not assume equivalency.
- PCOS has four recognized phenotypes. A treatment that works well for one person may not work the same way for another with a different hormonal pattern.
- Weight loss alone doesn't resolve PCOS. Some studies show improvements in ovulation and androgen levels, but the condition doesn't disappear. Ongoing monitoring with a provider matters.
- Side effects, including nausea, delayed gastric emptying, and in rare cases pancreatitis, are real. A 15-second video with upbeat music doesn't show those weeks.
The bottom line on this format
This video is not disinformation. It's a person sharing what appears to be a genuinely positive personal outcome. But the format does real work in normalizing GLP-1 medications as a simple fix for a complex endocrine condition, and that framing deserves scrutiny. If you're watching PCOS transformation content and making treatment decisions based on it, you're skipping several conversations you need to have with an actual clinician. The science on GLP-1 and PCOS is promising, not settled.